AmgenAMGN

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$196B

Price

$363.47

Today

−0.0%

Return YTD

+11.1%

Return 1Y

+22.6%

P/E

25.2

P/S

5.3

P/B

21.4

Data as of 2026-07-10 · updates daily after U.S. close

Theme exposure

BiotechOncologyObesity exposureObesity

In the value chain

Products & services

Oncology & haematology
Immunology
Obesity pipeline (MariTide)

Competitors

AbbVie
Novo Nordisk (obesity)
Eli Lilly

Risks

Patent expirations
Clinical risk in pipeline

Same segment: Biotech & innovation

Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN Alnylam PharmaceuticalsALNY ModernaMRNA BiogenBIIB IncyteINCY United TherapeuticsUTHR

See where Amgen sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →